These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30720113)

  • 1. MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells.
    Ren L; Deng B; Saloura V; Park JH; Nakamura Y
    Oncol Rep; 2019 Apr; 41(4):2540-2548. PubMed ID: 30720113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
    Inoue H; Kato T; Olugbile S; Tamura K; Chung S; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y; Park JH
    Oncotarget; 2016 Mar; 7(12):13621-33. PubMed ID: 26871945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
    Keysar SB; Le PN; Miller B; Jackson BC; Eagles JR; Nieto C; Kim J; Tang B; Glogowska MJ; Morton JJ; Padilla-Just N; Gomez K; Warnock E; Reisinger J; Arcaroli JJ; Messersmith WA; Wakefield LM; Gao D; Tan AC; Serracino H; Vasiliou V; Roop DR; Wang XJ; Jimeno A
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27634934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Hippo effector TAZ promotes cancer stemness by transcriptional activation of SOX2 in head neck squamous cell carcinoma.
    Li J; Li Z; Wu Y; Wang Y; Wang D; Zhang W; Yuan H; Ye J; Song X; Yang J; Jiang H; Cheng J
    Cell Death Dis; 2019 Aug; 10(8):603. PubMed ID: 31399556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma.
    Lee SH; Oh SY; Do SI; Lee HJ; Kang HJ; Rho YS; Bae WJ; Lim YC
    Br J Cancer; 2014 Nov; 111(11):2122-30. PubMed ID: 25321191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.
    Chlenski A; Park C; Dobratic M; Salwen HR; Budke B; Park JH; Miller R; Applebaum MA; Wilkinson E; Nakamura Y; Connell PP; Cohn SL
    Mol Cancer Ther; 2019 Mar; 18(3):507-516. PubMed ID: 30674566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells.
    Kato T; Inoue H; Imoto S; Tamada Y; Miyamoto T; Matsuo Y; Nakamura Y; Park JH
    Oncotarget; 2016 Apr; 7(14):17652-64. PubMed ID: 26933922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma.
    Bayo P; Jou A; Stenzinger A; Shao C; Gross M; Jensen A; Grabe N; Mende CH; Rados PV; Debus J; Weichert W; Plinkert PK; Lichter P; Freier K; Hess J
    Mol Oncol; 2015 Oct; 9(8):1704-19. PubMed ID: 26040981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma.
    Kiseljak-Vassiliades K; Zhang Y; Kar A; Razzaghi R; Xu M; Gowan K; Raeburn CD; Albuja-Cruz M; Jones KL; Somerset H; Fishbein L; Leong S; Wierman ME
    Endocrinology; 2018 Jul; 159(7):2532-2544. PubMed ID: 29790920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness.
    Jing C; Duan Y; Zhou M; Yue K; Zhuo S; Li X; Liu D; Ye B; Lai Q; Li L; Yao X; Wei H; Zhang W; Wu Y; Wang X
    Theranostics; 2021; 11(6):2655-2669. PubMed ID: 33456565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MELK and EZH2 Cooperate to Regulate Medulloblastoma Cancer Stem-like Cell Proliferation and Differentiation.
    Liu H; Sun Q; Sun Y; Zhang J; Yuan H; Pang S; Qi X; Wang H; Zhang M; Zhang H; Yu C; Gu C
    Mol Cancer Res; 2017 Sep; 15(9):1275-1286. PubMed ID: 28536141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing SOX2 Expression by RNA Interference Inhibits Proliferation, Invasion and Metastasis, and Induces Apoptosis through MAP4K4/JNK Signaling Pathway in Human Laryngeal Cancer TU212 Cells.
    Yang N; Wang Y; Hui L; Li X; Jiang X
    J Histochem Cytochem; 2015 Sep; 63(9):721-33. PubMed ID: 26001828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-1181 inhibits stem cell-like phenotypes and suppresses SOX2 and STAT3 in human pancreatic cancer.
    Jiang J; Li Z; Yu C; Chen M; Tian S; Sun C
    Cancer Lett; 2015 Jan; 356(2 Pt B):962-70. PubMed ID: 25444909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.
    Ji J; Yu Y; Li ZL; Chen MY; Deng R; Huang X; Wang GF; Zhang MX; Yang Q; Ravichandran S; Feng GK; Xu XL; Yang CL; Qiu MZ; Jiao L; Yang D; Zhu XF
    Theranostics; 2018; 8(6):1494-1510. PubMed ID: 29556337
    [No Abstract]   [Full Text] [Related]  

  • 15. AFF4 promotes tumorigenesis and tumor-initiation capacity of head and neck squamous cell carcinoma cells by regulating SOX2.
    Deng P; Wang J; Zhang X; Wu X; Ji N; Li J; Zhou M; Jiang L; Zeng X; Chen Q
    Carcinogenesis; 2018 Jul; 39(7):937-947. PubMed ID: 29741610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 3q oncogenes SEC62 and SOX2 on lymphatic metastasis and clinical outcome of head and neck squamous cell carcinomas.
    Bochen F; Adisurya H; Wemmert S; Lerner C; Greiner M; Zimmermann R; Hasenfus A; Wagner M; Smola S; Pfuhl T; Bozzato A; Al Kadah B; Schick B; Linxweiler M
    Oncotarget; 2017 Jan; 8(3):4922-4934. PubMed ID: 28002801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autophagy regulates the cancer stem cell phenotype of head and neck squamous cell carcinoma through the noncanonical FOXO3/SOX2 axis.
    Chen Y; Zhao H; Liang W; Jiang E; Zhou X; Shao Z; Liu K; Shang Z
    Oncogene; 2022 Jan; 41(5):634-646. PubMed ID: 34795388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
    Kohler RS; Kettelhack H; Knipprath-Mészaros AM; Fedier A; Schoetzau A; Jacob F; Heinzelmann-Schwarz V
    Gynecol Oncol; 2017 Apr; 145(1):159-166. PubMed ID: 28214016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activator inhibitor-1 as regulator of tumor-initiating cell properties in head and neck cancers.
    Lee YC; Yu CC; Lan C; Lee CH; Lee HT; Kuo YL; Wang PH; Chang WW
    Head Neck; 2016 Apr; 38 Suppl 1():E895-904. PubMed ID: 25974262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo.
    Ikeda Y; Sato S; Yabuno A; Shintani D; Ogasawara A; Miwa M; Zewde M; Miyamoto T; Fujiwara K; Nakamura Y; Hasegawa K
    J Gynecol Oncol; 2020 Nov; 31(6):e93. PubMed ID: 33078598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.